



Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

Shilpa House # 12-6-214/A-1, Hyderabad Road,
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532-238704, Fax : +91-8532-238876

CIN No. L85110KA1987PLC008739

E-mail : info@vbshilpa.com Website : http://www.vbshilpa.com

01st January 2019

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

Sub: Intimation U/R 30 of the SEBI (LODR) Regulations- Reg.

Ref: Stock Code: NSE: SHILPAMED/BSE-530549

This is to inform you that the Company has received U.S. Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL Injection USP, 40 mg/2mL and 100 mg/5mL (20mg/mL) Single Dose Vials.

Irinotecan injection is used in the treatment of patients with metastatic carcinoma of the colon or rectum.

According to IQVIA MAT Q2 2018 data, the US market for Irinotecan HCL approximately USD 18 million.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**


MADHUSUDHAN REDDY
Company Secretary &
Compliance Officer

